The close of the last week also saw the close of a 7-year litigation invalidating the patents protecting Roche’s osteoporosis drug, Boniva®.
Hoffman LaRoche (in collaboration with Genentech) is the maker of Boniva®, formulation of the bisphosphonate ibandronate which is taken monthly. The FDA ... (more)
I previously blogged about the ongoing dispute between Asahi and Actelion over Actelion’s alleged attempts to sabotage Asahi’s efforts to obtain FDA approval for the use of fasudil to treat pulmonary arterial hypertension in the United States.
At the time of my last blog post, the California Co... (more)
This blog entry is about one of those rare cases in which two generic drugmakers are at odds with each other over market exclusivity. This case is made more curious still because of the novel (though ultimately unsuccessful) strategy employed by one of the generic drugmakers to cancel the 180-da... (more)